It is no longer just small biotechs that are taking aim at coronavirus: Gilead Sciences and Glaxosmithkline are getting involved too, albeit via different routes.
Digital health is a core focus for Philips. Might more acquisitions be on the way?
Pfizer’s chief executive has pledged to throw money at the pharma giant’s thin pipeline and shirk financial engineering, but only canny deal-making will keep investors on…
Abbott is cueing up launch after launch for 2020, while J&J is pinning its device hopes to robotic surgery.
Available to download for free now, our annual preview takes a data-driven look at 2020. Uncover biopharma’s biggest growth drivers, and see where the money is flowing.
Paul Hudson has laid out his vision for Sanofi and it does not include diabetes or me-too products.
Healx's "hypothesis-free" approach proves a big draw to investors despite the early-stage nature of the group's projects.
A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…